Abstract library

1006 results for "duplicate malignant disease".
#884 Simultanenous Duplicate Malignant Disease-Adenocarcinoma of the Colon and Disseminated Neuroendocrine Tumor
Introduction: Fifty-nine-year old man, under examination due to weight loss, enterorrhagia, general abdominal discomfort. Endoscopy detected tumorous infiltration 20 cm from the anus, bleeding. Histology: adenocarcinoma. CT abdomen detected liver lesion. The lesion was hypervascularized, and the CT picture was atypical for metastatic adenocarcinoma. CT chest: tumor lesion in the left lower segment, metastatic LN in mediastinum. According to the CT, the picture is atypical for metastases.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: M.D. Lenka Ostrizkova
Authors:
#21 Peptide Receptor Radioligand Therapy (PRRT) is an Effective Treatment for the Long-Term Stabilization of Malignant Gastrinomas
Introduction: Gastrinomas represent a rare group of neuroendocrine tumors usually located in the duodenum or pancreas. They secrete gastrin, which is responsible for the clinical picture of severe acid-related peptic disease and diarrhea, known as the Zollinger-Ellison syndrome (ZES). While symptomatic control may be achieved with proton-pump inhibitors (PPIs) and somatostatin analogues (SSAs) treatment, little data is known regarding the possible anti-tumor effect of the peptide receptor radioligand therapy (PRRT) in gastrinoma patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Simona Grozinsky-Glasberg
Authors:
#142 The role of 18F DOPA-PET in a case of malignant pheochromcytoma
Introduction: Pheocromocytoma is a rare tumor arising from chromaffin cells of adrenal medullary or extra adrenal paraganglionic tissue. Histological criteria cannot differentiate benign from malignant pheocromocytomas. The diagnosis of a malignant pheocromocytoma requires local invasion, recurrence and documented metastatic disease. The radionuclide scanning (123I - 131I-MIBG) is a fundamental diagnostic tool used to confirm the biochemical and radiological diagnosis of pheochromocytoma. In fact, MIBG scanning may confirm that the visualised lesion in an adrenal gland is indeed a pheochromocytoma and detect extra-adrenal paraganglionic tissue. However, MIBG scans are negative in around 15% of benign pheochromocytomas and in up to 50% of malignant ones. Other radionuclide techniques (18FDG-PET, 18F-DOPA-PET, 18F-FDA-PET) have been successfully used in investigation of pheochromocytomas. 18F-DOPA-PET and 18F-FDA-PET have been reported to be highly sensitive and specific for benign pheochromocytomas, while 18FDG-PET can be useful for malignant lesions with higher metabolic activity.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Laura De Marinis
Authors:
#416 A Rare Case of Cushing Syndrome Caused by an Ectopic ACTH-Secreting Pancreatic Neuroendocrine Tumor in a Patient with Von Hipple-Lindau Disease
Introduction: Von Hipple-Lindau (VHL) disease is a rare autosomal dominant disorder, that causes the susceptibility to various tumors, both benign and malignant. The most frequent tumors are central nervous system haemangioblastomas, especially cerebellum and retinal haemangioblastomas, renal cell carcinoma /renal cysts and pheocromocytoma.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Andrea Lania
Authors:
#177 Dissociation Between Iodine-131 meta-iodobenzylguanidine (MIBG) Scintigraphy and Radiolabeled Octreotide in the Localization and Management of Sporadic Malignant Pheochromocytoma: An Impact on Management
Introduction: The Rx of malignant pheochromocytomas w/negative MIBG scan remains a challanging problem. Octreoscan is helpful in localization and Rx planning in such cases. Rx using SST analog & PRRT is a desirable goal.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Mohammed NMI Ahmed
Authors:
#640 Chomogranin A, NSE, and 5-Hydroxyindolacetic Acid Measurements in Malignant Carcinoids
Introduction: GEP-NETs are a heterogeneous group of cancers more common in the small intestine which are usually asymptomatic. In patients with malignant carcinoids, a number of tumor markers (TMs) have been considered enclosing urinary 5-hydroxyindolacetic acid (5-HIAA), chromogranin A (CgA), and neuron-specific enolase (NSE) serum levels measurements. Unfortunately, the sensitivity of each TM largely depends on disease extent and the presence of functioning tumors, and thus their usefulness is still unclear.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Professor Franco Lumachi
Authors:
#2164 A Case of Carcinoid Induced Heart Disease
Introduction: Carcinoid Heart disease is a common disease with neuroendocrine malignancies that invade the liver due to the paraneoplastic effects of vasoactive substances such as 5-hydroxytryptamine, histamine and tachykinins released by malignant cells rather than any direct metastatic involvement of the heart.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: doctor Suhel Ashraff
Authors:
#1924 Multimodal Treatment of a Metastatic Pancreatic NeuroEndocrine Tumor in Von Hippel Lindau Disease
Introduction: Von Hippel-Lindau disease (VHL) is an inherited neoplastic syndrome: pancreatic lesions in 35-77% of cases, usually serous cystic adenoma (SCA), but 5-17% are non-functioning (NF) NeuroEndocrine tumors (NETs).
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Anna Caterina Milanetto
Authors:
#22 A Case Illustrative of Phenotypic Heterogeneity and Challenges in the Management of Paraganglioma
Introduction: Paragangliomas (PGLs) are extra-adrenal, usually benign, highly vascularized tumors that originate from neural-crest-derived chromaffin cells. These tumors are subdivided as either sympathetic or parasympathetic, depending on their location and catecholamine production. Sympathetic PGLs are situated along the abdominal sympathetic trunk and usually produce catecholamines, whereas parasympathetic PGLs are located in the head and neck, and these usually do not produce catecholamines. PGLs may present as sporadic or inherited tumor syndrome, including MEN 2, with RET germline mutations, von Hippel-Lindau (VHL) disease due to germline mutations in VHL gene, and pheochromocytoma-PGL syndrome. The latter is frequently a hereditary condition and is caused by germline mutations in the SDHB, SDHC, or SDHC genes. Patients with familial PGLs may present at a younger age, often as multifocal tumors, with an increased risk of recurrence and a higher frequency of malignancy in those with SDHB mutations. SDH mutations induce angiogenesis and tumorogenesis through the inhibition of hypoxia-inducible factors (HIF)-propyl hyroxylase. A younger age at onset, malignancy, and a positive family history are clinical parameters of high specificity, but low sensitivity for diagnosis. Genetic analysis for mutations in SDH genes for the patient and family members, and surveillance for the affected patient and family members, are necessary where there are no clear clinical or family indicators for the syndrome. We present a case of a large abdominal malignant PGL in a 20-year-old pt. that went on without clinical detection for at least three years.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohammed Ahmed
Authors:
#431 Everolimus Controlled Resistant Hypoglycemia in Malignant Insulinoma
Introduction: A pancreatic neuroendocrine carcinoma with liver metastases was diagnosed on July 2006 in a 65-year-old man. He was treated with octreotide LAR 30 mg for three years. At liver progression he was enrolled in a multicenter Italian trial titled “XELBEVOCT” with Bevacizumab + Metronomic Capecitabine + Octreotide LAR 30 mg. After seven months, the patient exhibited severe hypoglycemic syndrome with HGT serum levels<30 mg/dl, insulin 150 microUI/ml, and C-peptide at upper normal limits. Endocrinologist prescribed prednisone, diazoxide and recombinant glucagon for hypoglicemic crisis, with little benefit. In March 2010, the patient was given radio-labelled Lu-177-OCTREOTATE treatment. After three cycles, hypoglicemic symptoms were still uncontrolled. CT scan showed stable disease.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Anna Ferrero
Authors: